Gene
|
Nucleotide change
|
Amino acid change
|
Clinical isolates (n = 111)
|
MDR-TB
(n = 12)
|
Polydrug resistant
(n = 0)
|
---|
Pansusceptible
(n = 108)
|
FQ mono-resistant
(n = 3)a
|
---|
gyrA
|
C(269) → T
|
Ala(90) → Val
|
–
|
–
|
–
|
–
|
T(271) → C
|
Ser (91) → Pro
|
–
|
–
|
–
|
–
|
A(281) → G
|
Asp(94) → Gly
|
–
|
1 (new case)
|
2 (XDR)b
|
–
|
gyrB
|
–
|
–
|
–
|
–
|
–
|
–
|
Phenotypically FQ resistant, without any gyrase mutations
|
–
|
2 (1 new, 1 relapse)
|
1
|
–
|
All phenotypically FQ resistant
|
–
|
3
|
3c
|
–
|
- Note: Pansusceptible: susceptible to all first-line anti-TB drugs, FQ mono resistance: being resistant only to FQ, but sensitive to all first-line TB drugs, MDR-TB: resistance to at least both isoniazid and rifampin, Polydrug resistance: resistance to more than one first-line anti-TB drug, other than both isoniazid and rifampin
- aThese three isolates were all related to Iranian patients. Two of them were new TB cases and one was a TB relapse
- bThese two MDR isolates were resistant to FQs and also they were found to be resistant against kanamycin and amikacin in another study by our colleagues on these isolates [30]. Both were TB treatment failure cases, one from Afghanistan and one from Kazakhstan
- cAll were treatment failure cases